ArticleBMC cancer2025

Effectiveness of axicabtagene ciloleucel versus conventional treatments as first-line therapy for high-risk large B-cell lymphoma: an external comparator study.

Ju Hwan Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.